UPDATE : Monday, May 25, 2020
Gene therapies’ potentials, challenges explained by Jeong Sae-im 2019-04-22 11:46
Why is TissueGene CEO silent about Invossa mislabeling? by Jeong Sae-im 2019-04-19 14:37
‘How Korean pharma companies can succeed in US’ by Lee Han-soo 2019-04-18 14:41
Kolon desperate to keep Invossa license amid suspicion of data fabrication by Lee Hye-seon 2019-04-18 11:16
Patients to file class-action suit against Kolon over Invossa by Jeong Sae-im 2019-04-17 14:58
‘Invossa lacked clinical evidence to be commercialized’ by Jeong Sae-im 2019-04-17 12:45
BIO KOREA 2019 aims to lead open innovation by Lee Han-soo 2019-04-17 12:42
Celltrion unveils P2 trial results for influenza antibody therapy by Lee Han-soo 2019-04-16 16:16
‘Kolon might have fabricated data to get Invossa approval’ by Jeong Sae-im 2019-04-16 11:07
[News Focus] Abbvie hits back at competitors selling Humira biosimilars in Europe by Lee Han-soo 2019-04-15 15:19
All Invossa products contained 293 cells, Kolon confirms by Jeong Sae-im 2019-04-15 11:31
Invossa license won’t be revoked: Kolon CEO by Jeong Sae-im 2019-04-12 11:40
Regulator, Kolon rebuked for slow response to Invossa problem by Jeong Sae-im 2019-04-11 14:46
Canada OKs Celltrion’s Truxima by Lee Han-soo 2019-04-11 11:33
Patients may file class-action lawsuit against Kolon for mislabeling Invossa by Jeong Sae-im 2019-04-10 14:41
Celltrion, iProgen to co-develop novel antibody-drug conjugates by Lee Han-soo 2019-04-09 16:04
Kolon’s foreign partners await cell analysis results by Jeong Sae-im 2019-04-08 14:28
Kolon Life Science criticized for poor quality control on Invossa by Jeong Sae-im 2019-04-05 12:27
‘Invossa, first treatment to have used cancerous cell lines’ by Jeong Sae-im 2019-04-04 15:24
Celltrion completes patient registration for Humira biosimilar by Lee Han-soo 2019-03-28 18:04
Back to Top